Introduction {#S0001}
============

Glioma was the most common type of brain cancer, accounting for almost 80% of brain malignancies.[@CIT0001] Gliomas were divided into grades I to IV, based on the World Health Organization (WHO) classification scheme.[@CIT0002] The 5-year survival rate for glioblastoma patients, accounting for 45% of all gliomas, was just 5--6%.[@CIT0003],[@CIT0004] Various risk factors were considered to be associated with gliomas, such as exposing to high doses of ionizing radiation, allergies or atopic disease, and hereditary genetic disorders (family history).[@CIT0005],[@CIT0006] Similar to other tumors, hereditary factors seem to be an important factor in the occurrence of glioma. It was reported that single-nucleotide polymorphisms (SNPs) were the most frequent single-nucleotide variations that occur in a specific position. Numerous SNPs, such as those in XRCC1/4, ERCC1/4, MGMT, PARP1, and MTHFR have been demonstrated to contribute to glioma susceptibility.[@CIT0001],[@CIT0007]

The thymidylate synthase (*TYMS*) gene is located at human chromosome band 18p11.32. *TYMS* is essential for *de novo* biosynthesis of thymidylate (TMP), cell proliferation and survival.[@CIT0008] Inhibition of *TYMS* expression leads to thymidylate depletion and thymineless death, accompanied by DNA damage, apoptosis, and chromosome aberrations.[@CIT0009] Currently, several *TYMS* SNPs have been reported to be correlated with susceptibility to cancers including breast, lung, gastric, colorectal, and ovarian cancers.[@CIT0010]--[@CIT0014]

A previous study presented that *TYMS* expressed positively in 27.39% of lymph node of low-grade glioma patients.[@CIT0015] However, no studies illuminated the association between *TYMS* gene polymorphism and the glioma risk. Therefore, this case-control study aimed to clarify the correlation between two common *TYMS* gene variants (rs1059394 C\>T, rs2847153 G\>A) and glioma susceptibility.

Materials And Methods {#S0002}
=====================

Study Population {#S0002-S2001}
----------------

The protocol of this study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University Shaanxi Province (Xi'an, China). All patients gave written informed consent prior to participation in the study. This study was conducted in accordance with the Declaration of Helsinki.

This study consisted of 605 patients with gliomas (mean age: 40.71±18.28 years) who underwent surgical resection; they were consecutively recruited between September 2010 and May 2014 at Tangdu Hospital, which is affiliated with the Fourth Military Medical University in China. Eligible patients were diagnosed with glioma based on imaging and pathology, and were untreated with chemotherapy or radiotherapy before surgery. Healthy controls included 1,300 age- and sex-matched healthy individuals (mean age: 41.68±13.54 years) who underwent a checkup at the same hospital during the same period of time. Basic characteristics of patients and controls were collected, including ethnicity, age, sex, WHO grade, extent of resection, radiotherapy, and chemotherapy strategy.

Genotyping Assay {#S0002-S2002}
----------------

Peripheral blood was collected in ethylenediaminetetraacetic acid tubes and stored at −80°C after centrifugation. We then extracted genomic DNA from whole blood using the Universal Genomic DNA Extraction Kit (TaKaRa, Kyoto, Japan). DNA concentrations were assessed using spectrophotometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA). In total, two tag-SNPs (rs1059394 and rs2847153) were selected in our study. The Multiplexed SNP Mass EXTEND assay was designed by Sequenom Mass ARRAY Assay Design (version3.0, Agena Bioscience, San Diego, CA, USA),[@CIT0016] which was referred to in previous studies.[@CIT0017]--[@CIT0019] SNP genotyping was carried out using Sequenom Mass-ARRAY RS1000. Sequenom Typer 4.0 software was used to analyze data.[@CIT0016],[@CIT0020] Primers of each SNP are presented in [Table 1](#T0001){ref-type="table"}.Table 1Primers Used For This StudySNP_ID1st-PCRP2nd-PCRPUEP_SEQ**rs1059394**ACGTTGGATGGTATCGACAGGATCATACTCACGTTGGATGCGACCTGTTGTAATTGCTCCcATTGCTCCTCATGTCC**rs2847153**ACGTTGGATGTCTTTAAGTAGGCTGGT\
CCCACGTTGGATGAGAAAAGATCTGGGAGG\
GTGgCAAAGAAGGGATCAG\
ACT[^2]

Genotype-Phenotype Association {#S0002-S2003}
------------------------------

eQTL are regions of the genome containing DNA sequence variants that influence the expression level of one or more genes. We conducted the expression quantitative trait loci (eQTL) analysis using GTEx portal web site ([[http://www.gtexportal.org/home/]{.ul}](http://www.gtexportal.org/home/)) to predict potential associations between the two SNPs and TYMS gene expression levels.[@CIT0021] The GTEx Portal provides open access to data including gene expression, QTLs, and histology images.

Statistical Analysis {#S0002-S2004}
--------------------

Statistical analyses were performed using the software R (version 3.5.1). The Chi-square test was used to examine Hardy- Weinberg equilibrium (HWE) based on gene frequencies in individuals. We used univariate logistic regression analysis to evaluate differences in the genotype distributions of the two SNPs between the cases and controls. The glioma risk associated with the *TYMS* rs1059394 and rs2847153 genotypes were estimated using odds ratios (ORs) and their 95% confidence intervals (CIs). For all tests, a two-tailed *P*-value \< 0.05 was considered statistically significant.

Results {#S0003}
=======

Characteristics Of The Study Population {#S0003-S2001}
---------------------------------------

All the participants were of Han Chinese Ethnicity. There were no significant differences between the two groups regarding age or sex (*P* = 0.195 and, *P* = 0.534, respectively). The patients included 335 (55.4%) men and 270 (44.6%) women, with 267 patients younger than 40 years of age, and 338 patients older than 40 years of age. A total of 382 (63.1%) patients were classified with low-grade glioma (WHO grades I--II) and 223 (36.9%) with high-grade glioma (WHO grades III--IV). There were 416 (68.8%) patients with glioma who underwent gross-total tumor surgical resection and 189 (31.2%) who underwent near-total or sub-total resection. In total, 545 (90.1%) patients received radiotherapy treatment, and 250 (41.3%) patients received chemotherapy. The basic characteristics of the participants are listed in [Table 2](#T0002){ref-type="table"}.Table 2The Characteristics Of Gliomas Cases And Cancer-Free ControlsCharacteristicsCasesControl*P* value\*Number6051300Age (mean ± SD)40.71±18.2841.68±13.540.195 \<40 years267561 ≥40 years3387390.688Sex Male335700 Female2706000.534WHO Grade I-II382 III-IV223Surgery STR & NTR189 GTR416Radiotherapy No60 Yes545Chemotherapy No355 Yes250[^3][^4]

TYMS Polymorphisms In The Patients With Glioma And Controls {#S0003-S2002}
-----------------------------------------------------------

The genotypic frequency for the *TYMS* rs1059394 and rs2847153 polymorphisms conformed to HWE (*P* = 0.53 and *P* = 0.47, respectively). The genotypic and allelic frequencies of *TYMS* rs1059394 and rs2847153 are presented in [Table 3](#T0003){ref-type="table"}. Compared with the wildtype genotype of rs1059394, we found that TT and CT+TT genotype carriers had significantly decreased glioma risk (TT to CC: OR = 0.71, 95% CI = 0.52--0.97, *P* = 0.03; CT+TT to CC: OR = 0.74, 95% CI =0.55--0.99, *P* = 0.04). However, no statistically significant difference was found between rs2847153 and glioma risk in genetic models (*P*﹥0.05).Table 3Genotype Frequencies Of *TYMS* Polymorphisms In Cases And ControlsModelGenotypeControl (n, %)Case (n, %)OR (95% CI)*P*-value\***rs1059394 HWE: *P=0.53*Co-dominant**CC131(10.1%)80 (13.2%)1.00 (reference) HeterozygoteCT548(42.1%)255 (42.2%)0.76(0.56--1.04)0.09 HomozygoteTT621(47.8%)270 (44.6%)0.71(0.52--0.97)0.03**Dominant**CC131(10.1%)80 (13.2%)1.00 (reference)CT+TT1169(89.9%)525(86.8%)0.74(0.55--0.99)0.04**Recessive**CC+CT679(52.2%)335(55.4%)1.00 (reference)TT621(47.8%)270(44.6%)0.88(0.73--1.07)0.20**Overdominant**CC+TT752(51.9%)350(57.8%)1.00 (reference)CT548(42.1%)255(42.2%)1.00(0.82--1.22)1.00**Allele**C810(31.2%)415(34.5%)1.00 (reference)T1790(68.8%)795(65.5%)0.87(0.75--1.00)0.05**rs2847153**^ª^ **HWE: *P=0.47*Co-dominant**GG534(41.1%)223(36.9%)1.00 (reference) HeterozygoteGA589(45.3%)295(48.9%)1.20(0.97--1.48)0.09 HomozygoteAA177(13.6%)86(14.2%)1.16(0.86--1.57)0.32**Dominant**GG534(41.1%)223(36.9%)1.00 (reference)GA+AA766(58.9%)381(63.1%)1.19(0.98--1.45)0.09**Recessive**GG+GA1123(86.4%)518(85.8%)1.00 (reference)AA177(13.6%)86(14.2%)1.05(0.80--1.39)0.71**Overdominant**GG+AA711(44.7%)309(51.2%)1.00 (reference)GA589(45.3%)295(48.8%)1.15(0.95--1.39)0.15**Allele**G1657(63.7%)741(61.3%)1.00 (reference)A943(36.3%)467(38.7%)1.11(0.96--1.28)0.16[^5][^6]

Relationship Between TYMS SNPs And Clinical Characteristics Of Glioma {#S0003-S2003}
---------------------------------------------------------------------

We evaluated the correlations between the rs1059394 and rs2847153 polymorphisms and clinical characteristics of patients with glioma, including age, sex, and WHO grade. As shown in [Table 4](#T0004){ref-type="table"}, in high-grade gliomas, the GA and GA+AA genotypes of rs2847153 were significantly increased, with the GG genotype as the reference (GA to GG: OR = 2.01, 95% CI = 1.39--2.91, *P* \< 0.001; GA+AA to GG: OR = 1.78, 95% CI =1.25--2.54, *P* \< 0.001). There was a balanced genotype distribution in rs1059394 polymorphisms ([Table 5](#T0005){ref-type="table"}).Table 4The Associations Between The *TYMS* rs2847153 Polymorphisms And Clinical Characteristics Of Gliomas PatientsCharacteristicsGenotype DistributionsGGGAAAGA+AAAge \<40/≥40106/117123/17238/48161/220 OR (95% CI)1.00 (Reference)1.27 (0.82--1.80)1.14 (0.69--1.89)1.23 (0.89--1.73) P-value\*0.1850.5970.208Sex Male/Female116/107169/12650/36219/162 OR (95% CI)1.00 (Reference)0.81 (0.57--1.15)0.78 (0.47--1.29)0.80 (0.58--1.12) P-value\*0.2330.3340.193WHO Grade I+II/III+IV159/64163/13259/27222/159 OR (95% CI)1.00 (Reference)2.01 (1.39--2.91)1.14 (0.66--1.95)1.78 (1.25--2.54) P-value\*\<0.0010.6410.001[^7][^8] Table 5The Associations Between The *TYMS* Rs1059394 Polymorphisms And Clinical Characteristics Of Gliomas PatientsCharacteristicsGenotype DistributionsCCCTTTCT+TTAge \<40/≥4038/42118/137111/159229/296 OR (95% CI)1.00 (reference)1.05 (0.63--1.74)1.30 (0.78--2.14)1.17 (0.73--1.87) P-value\*0.8480.3110.515Sex Male/Female13/37145/110147/123292/233 OR (95% CI)1.00 (reference)0.88 (0.53--1.46)0.97 (0.59--1.61)0.93 (0.58--1.49) P-value\*0.6250.9130.754WHO Grade I+II/III+IV46/34162/93174/96336/189 OR (95% CI)1.00 (reference)0.78 (0.47--1.30)0.75 (0.45--1.25)0.76 (0.47--1.23) P-value\*0.3330.260.263[^9][^10]

Expression Quantitative Trait Loci {#S0003-S2004}
----------------------------------

To investigate the potential biological effects of the two significant SNPs on the TYMS gene expression, we explored eQTL analysis by GTEx portal. The results indicated that genotypes of both SNPs were significantly associated with TYMS gene expression in transformed fibroblasts cells ([Figure 1](#F0001){ref-type="fig"}).Figure 1Analysis of the rs1059394 and rs2847153 polymorphisms in the TYMS gene in transformed fibroblast cells. Shown is the eQTL analysis for the (**A**) rs1059394 and (**B**) rs2847153 polymorphisms in the TYMS gene in transformed fibroblast cells (GTEx portal).

Discussion {#S0004}
==========

Gliomas are highly malignant with a poor prognosis, although early diagnosis and improved treatment are widely implemented. In addition, there were 296,851 new cases of brain and nervous system cancer, and glioma accounted for the majority of brain cancers.[@CIT0022],[@CIT0023] In China, 1,016,000 new cases of brain and central nervous system cancer were reported in 2015.[@CIT0024] It was suggested that genetic factors were primarily responsible for glioma genesis,[@CIT0025] and there was still a lack of prospective molecular biomarkers for glioma.

*TYMS* is reported to be associated with folate metabolism, and it catalyzes conversion of deoxyuridine-5́- monophosphate into deoxythymidine-5́-monophosphate. It is suggested that *TYMS* down regulation can influence DNA repair mechanisms, which is related to cell transformation and cancer development.[@CIT0026] *TYMS* is also an important target of 5-fluorouracil (5-FU), inhibition of *TYMS* by fluorodeoxyuridine monophosphate (an active metabolite of 5-FU) results in DNA damage and cell death.[@CIT0015],[@CIT0027] Therefore, functional genetic variants of *TYMS* may lead to cancer, and *TYMS* maybe a molecular biomarker. It is indicated that *TYMS* genetic polymorphisms are correlated with the susceptibility of different cancers.

The *TYMS* polymorphisms rs1059394 (C\>T) and rs2847153 (G\>A) have been investigated in a few cancers. Rs1059394 TT genotypes were found to be correlated with a significantly increased risk of gastric cancer.[@CIT0012] Further stratified analysis indicated that the rs1059394 T variant allele was associated with a significantly decreased risk of breast cancers in patients with a smoking history.[@CIT0010] In addition, as for patients with non-small cell lung cancer, rs2847153 in *TYMS* may be helpful for prognosis and personalized treatment.[@CIT0028] There have been no studies about *TYMS* polymorphisms and glioma risk previously.

Our study evaluated the relationship between *TYMS* polymorphisms (rs1059394 and rs2847153) and glioma risk. Compared with the wildtype genotype of rs1059394, we found that TT and CT+TT genotype carriers had a significantly decreased glioma risk, indicating that rs1059394 C\>T was associated with the low susceptibility of glioma. In high-grade gliomas, the GA and GA+AA genotypes of rs2847153 were significantly increased, which means that GA or GA+AA genotypes may predict a worse prognosis. Therefore, the polymorphism of *TYMS* may be biomarkers of clinical outcomes and personalized treatment. A study evaluated the expression of *TYMS* gene in the metastatic lymph node and primary foci of low-grade glioma, with a significant positive TYMS expression.[@CIT0015] The specific mechanism of this is unclear, which is a potential subject on high-grade glioma for further evaluation.

Our study also had some limitations. Firstly, all samples originated from a hospital in the northwest region of China, which inevitably led to selection bias. Second, we did not stratify our analysis for tumor subtypes because the sample size was circumscribed. Third, due to the limits of data, we did not analyze the impact of other factors, such as dose radiation exposure, lifestyle, family history, tumor size and outcome. Hence, this deserves further investigation with a multi-center, case-control study in the future.

To summarize, our study indicated that *TYMS* polymorphisms were associated with glioma susceptibility. The rs1059394 C\>T variant could decrease the risk of glioma. In addition, the rs2847153 G\>A variant might predict worse survival in glioma patients. Further functional and multi-center case-control studies are needed to clarify the association between *TYMS* polymorphisms and the susceptibility of glioma.
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[^2]: **Notes:** 1st-PCRP, reverse primer; 2nd-PCRP, forward primer.

[^3]: **Note:** \**T*-test or two-sided *χ*^2^-test.

[^4]: **Abbreviations:** STR, subtotal resection; NTR, near total resection; GTR, gross total resection; SD, Standard Deviation.

[^5]: **Notes:** \*Univariate logistic regression analysis for the distributions of genotype and allele frequencies. Adjusted for age and sex. ^ª^Genotype deletion: cases n=1. The Co-dominant, Dominant, Recessive, Overdominant, Allele represented five models.

[^6]: **Abbreviations:** HWE, Hardy--Weinberg Equilibrium; OR, Odd Ratio; CI, Confidence Interval.

[^7]: **Notes:** \*Univariate logistic regression analysis for the distributions of genotype frequencies. Genotype distributions including all the genotype of *TYMS* rs2847153 polymorphisms.

[^8]: **Abbreviations:** OR, Odd Ratio; CI, Confidence Interval.

[^9]: **Note:** \*Univariate logistic regression analysis for the distributions of genotype frequencies.

[^10]: **Abbreviations:** OR, Odd Ratio; CI, Confidence Interval.
